October 4, 2017
ImmuPharma, Lanstead Capital finish sharing deal, Phase III results for Lupuzor in Q1 2018
ImmuPharma has completed a sharing agreement with Lanstead Capital from February 2016, for supporting of ImmuPharma’s pivotal Phase III clinical trial…